| ▲ | ejstronge 3 days ago | |
This is an area I work in professionally so I keep up with the technical side of things. > once you start adding more than one item to a cell it doesn't always work out. Very true, but the amounts of money at stake would justify the relatively inexpensive cost of hooking cells up to the already-available ER/TR-responsive gene elements. > but I don't believe any before have contained these immune escaping edits Hard to say, I'm not an expert on immune escape. It's an old idea, however, so I imagine it's been used in other pre-clinical or Phase 1 settings. > I believe all of those treatments are cancer treatments which allow for a different level of risk I imagine you're speaking about allogeneic treatment? Either way, this isn't true at all - here's a list of current treatments for diabetes alone: | ||